NCT00875628View on ClinicalTrials.gov

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Healthy Volunteers
Interventions
DRUG

PF-00868554 or Placebo

Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days

DRUG

PF-00868554 or Placebo

Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days

DRUG

PF-00868554 or Placebo

Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days

Trial Locations (1)

91206

Pfizer Investigational Site, Glendale

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY